[免疫血小板缺血的差异诊断和治疗]
1Klinik für Hämatologie, Onkologie und Palliativmedizin, Marien-Hospital Düsseldorf, Deutschland.
Deutsche medizinische Wochenschrift (1946)
|July 16, 2024
概括
免疫性血小板缺血 (ITP) 涉及自身抗体攻击血小板,往往使诊断具有挑战性. 治疗从皮质类固醇和IVIG进展到先进的疗法,如血栓形成素受体激活剂和Fostamatinib.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 免疫性血小板缺血症 (ITP) 是一种自身免疫性疾病,其特征是针对血小板表面抗原的自身抗体.
- 在约50%的病例中,由于无法识别特定的葡萄糖蛋白抗体,ITP的诊断往往是排除的一个.
- 不同诊断必须排除血小板缺血的其他原因,包括EDTA诱导的伪血小板缺血,药物诱导的血小板缺血和遗传性疾病.
研究的目的:
- 为提供免疫血小板缺血 (ITP) 的全面概述.
- 概述ITP的诊断挑战和差异性考虑.
- 详细介绍ITP管理的治疗策略.
主要方法:
- 关于ITP病理生理学,诊断和治疗的文献综述.
- 分析当前的临床指导方针和治疗选择.
- 综合关于一线,二线和进一步治疗线的信息.
主要成果:
- ITP是由对血小板表面抗原的自身抗体定义的,这使得诊断复杂化.
- 第一线治疗包括皮质类固醇和静脉注射免疫球蛋白.
- 二线和先进疗法包括血栓形成素受体激动剂,rituximab,脊髓切除术,Fostamatinib和免疫抑制剂.
结论:
- 准确诊断ITP需要排除低血小板计数的其他原因.
- 采用逐步治疗方法,根据患者的反应和疾病严重程度升级治疗.
- 目前的治疗选择提供了各种有效管理ITP的策略.
相关概念视频
Tumor Immunotherapy
504
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
504
Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
668
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
668
Disorders of Hemostasis
820
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
820
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


